NCT03655691

ET-01 in Subjects With Lateral Canthal Lines, LCL-207

Clinical Trial to Evaluate ET-01 in Subjects With Lateral Canthal Lines

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 79 (actual)
• Sponsor: Eirion Therapeutics Inc. · Industry
• Sex: All
• Age: 25 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).

Detailed description

This product is being tested for its ability to reduce lateral canthal lines, also known as Crow's Feet.

Conditions

• Lateral Canthal Lines
• Crow's Feet

Interventions

Type	Name	Description
BIOLOGICAL	Vehicle	Vehicle Formulation
BIOLOGICAL	botulinum toxin, Type A	botulinum toxin, Type A, lower Dose 1, administered once, topically, at Baseline
BIOLOGICAL	botulinum toxin, Type A	botulinum toxin, Type A, higher Dose 2, administered once, topically, at Baseline

Timeline

• Start date: 2018-08-16
• Primary completion: 2018-11-09
• Completion: 2019-04-11
• First posted: 2018-08-31
• Last updated: 2022-04-21
• Results posted: 2022-02-18

Locations

6 sites across 1 country: United States

Regulatory

• FDA-regulated drug study